Industry News

Alpha IMS microchip eligible for reimbursement in Germany

Retina Implant AG’s Alpha IMS microchip has received NUB innovation status and is now eligible for reimbursement by Germany’s statutory health insurance system, according to a company press release.

The German statutory health insurance system, which insures 90% of German citizens, reached an agreement with six German University clinics and teaching hospitals to make the Alpha IMS microchip available to patients with late-stage retinitis pigmentosa, the release said.

The wireless subretinal implant is placed under the retina, in the macular region, and simulates functioning nerve cells in patients with late-stage retinitis pigmentosa.

Alpha IMS received CE mark designation in the European Union in July 2013, according to the release.

Retina Implant AG’s Alpha IMS microchip has received NUB innovation status and is now eligible for reimbursement by Germany’s statutory health insurance system, according to a company press release.

The German statutory health insurance system, which insures 90% of German citizens, reached an agreement with six German University clinics and teaching hospitals to make the Alpha IMS microchip available to patients with late-stage retinitis pigmentosa, the release said.

The wireless subretinal implant is placed under the retina, in the macular region, and simulates functioning nerve cells in patients with late-stage retinitis pigmentosa.

Alpha IMS received CE mark designation in the European Union in July 2013, according to the release.